Fmr LLC Sells 1,949,890 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)

FMR LLC trimmed its position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) by 25.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,865,106 shares of the company's stock after selling 1,949,890 shares during the period. FMR LLC owned about 11.12% of ALX Oncology worth $10,674,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company's stock worth $39,000 after purchasing an additional 5,200 shares during the period. SG Americas Securities LLC increased its stake in ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company's stock worth $50,000 after purchasing an additional 6,888 shares during the period. Hsbc Holdings PLC bought a new stake in shares of ALX Oncology in the 2nd quarter worth approximately $63,000. GSA Capital Partners LLP bought a new stake in shares of ALX Oncology in the 3rd quarter worth approximately $88,000. Finally, AQR Capital Management LLC grew its position in shares of ALX Oncology by 50.7% in the 2nd quarter. AQR Capital Management LLC now owns 18,079 shares of the company's stock worth $109,000 after buying an additional 6,080 shares during the last quarter. 97.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ALXO. UBS Group cut their price objective on ALX Oncology from $25.00 to $4.00 and set a "buy" rating on the stock in a research report on Friday, August 16th. Cantor Fitzgerald reiterated an "overweight" rating on shares of ALX Oncology in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, ALX Oncology has an average rating of "Moderate Buy" and a consensus target price of $10.67.

ALX Oncology Stock Down 6.0 %

Shares of NASDAQ ALXO traded down $0.09 during mid-day trading on Thursday, hitting $1.42. 2,638,562 shares of the stock traded hands, compared to its average volume of 801,477. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology Holdings Inc. has a 52 week low of $1.19 and a 52 week high of $17.83. The company has a market cap of $74.90 million, a price-to-earnings ratio of -0.51 and a beta of 1.04. The stock has a fifty day moving average price of $1.49 and a 200-day moving average price of $3.74.

Insider Activity at ALX Oncology

In other ALX Oncology news, Director Rekha Hemrajani purchased 30,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were purchased at an average cost of $1.55 per share, with a total value of $46,500.00. Following the completion of the acquisition, the director now directly owns 33,000 shares in the company, valued at $51,150. This trade represents a 1,000.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 33.40% of the stock is currently owned by corporate insiders.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.